GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TsGRM Genetiko PAO GECO.ME · RUB

N/A · MOEX · 🇷🇺 Russia

Compare

16.01

+3.89%

Close of 9 Nov 2026, in RUB

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About TsGRM Genetiko PAO

Its shares trade on MOEX under the ticker GECO.ME. It has been listed since 25 April 2023. In the fiscal year to 31 December 2024, it reported revenue of RUB 426.0m and a net loss of RUB 13.3m. At that date it held total assets of RUB 881.0m and shareholders' equity of RUB 600.4m.

TsGRM Genetiko PAO is a RU-based company operating in industry. The company is headquartered in Moscow, Moscow. The company went IPO on 2023-04-25. TsGRM Genetiko PAO is a Russia-based company primarily engaged in provision of medical services. The firm comprises laboratory and production complexes that provide a range of medical genetic services for both doctors and patients. The firm conducts complex genetic diagnostics of hereditary diseases and reproductive disorders. The firm's structure consists of four laboratories: Next-Generation Sequencing (NGS) laboratory; Non-Invasive Prenatal Testing (NIPT) laboratory; Oncogenetics laboratory; and Genotyping laboratory.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
25 Apr 2023
Website
genetico.ru ↗

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • TsGRM Genetiko PAO operates four specialized laboratories in Moscow for genetic diagnostics.
  • The company provides comprehensive genetic services including NGS and NIPT for hereditary diseases.
  • TsGRM Genetiko PAO offers oncogenetics and genotyping services to medical professionals in Russia.

Weaknesses

  • The company's services are limited to Moscow and Russia with no international expansion.
  • TsGRM Genetiko PAO has no presence in other countries or global markets.
  • The firm's IPO on April 25, 2023, indicates limited market experience.

Opportunities

  • TsGRM Genetiko PAO can expand its genetic services to other Russian regions beyond Moscow.
  • The growing demand for genetic diagnostics in Russia presents new market opportunities.
  • The company may develop partnerships with international genetic research institutions.

Threats

  • TsGRM Genetiko PAO faces competition from other Russian medical service providers.
  • The Russian healthcare sector may experience regulatory changes affecting genetic services.
  • Economic instability in Russia could reduce demand for non-essential medical services.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.